Lumiliximab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameLumiliximab
Drug Alias NameST-152鲁昔单抗IDEC-152Anti-CD23 monoclonal antibody - IDECGomiliximab +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionImmunoglobulin epsilon Fc receptor antagonists
TargetsImmunoglobulin epsilon Fc receptor
Therapy Area/IndicationsLymphomaLeukemia, Lymphocytic, Chronic, B-CellLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Idec
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiogen IncNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsLymphomaLeukemia, Lymphocytic, Chronic, B-CellLeukemia

Other Information

ATC CodeN/A
Related LinksDrugBank